TABLE 1.
Characteristics of the study population (n = 709)
| Parameter | Value |
|---|---|
| Age, years † | 52 (43–57) |
| Male sex, n (%) | 572 (80.7) |
| HIV infection way, n (%) | |
| Drug use | 277 (39) |
| Sexual | 387 (54.6) |
| Other and unknown | 45 (6.3) |
| Active tobacco smokers, n (%) | 370 (52.2) |
| Daily alcohol intake ≥50 g, n (%) | 53 (7.5) |
| Active opiate use, n (%) | 48 (6·8) |
| CDC clinical category C, n (%) | 187 (26.4) |
| Nadir CD4 cell counts (cel/μl) [Link] , ‡ | 239 (77–400) |
| Baseline CD4 cell counts (cel/μl) † | 637 (414–844) |
| Baseline plasma HIV‐RNA <200 c/ml, n (%) | 664 (93.7) |
| ART combination § | |
| TAF or TDF/FTC‐based | 339 (47.8) |
| ABC/3TC‐based | 97 (13.7) |
| 3TC‐including dual therapy | 168 (23.7) |
| Nucleos(t)ide‐free | 103 (14.5) |
| Positive plasma HBsAg | 18 (2.5) |
| Positive plasma anti‐HCV | 314 (44.3) |
| Active HCV infection | 3 (0.4) |
| Charlson index, n (%) | |
| 0 | 206 (29.1) |
| 1‐2 | 300 (42.3) |
| 3‐5 | 145 (20.5) |
| ≥5 | 58 (8.2) |
Abbreviations: ABC, abacavir; ART, antiretroviral therapy; FTC, emtricitabine; HBV, hepatitis B virus; TAF, tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate; 3TC, Lamivudine.
†
Median (Q1‐Q3).
‡
Available data for 601 patients
§
707 patients on ART.